ABCA6 Genotype

Some people run a high cholesterol number despite a clean diet, regular exercise, and an otherwise reassuring family history. Part of that mystery may live inside genes that handle fat transport inside cells, and ABCA6 (ATP Binding Cassette Subfamily A Member 6) is one such gene. A rare protein-changing version of this gene has been tied in a large human study to higher LDL and total cholesterol, with reported effect sizes similar in magnitude to single variants in better-known genes like LDLR (the LDL receptor). However, follow-up work in animal models has not confirmed a direct causal role for ABCA6 in cholesterol handling, so the picture is still incomplete.

This test reads a one-time genetic fingerprint that does not change over your lifetime. It will not show you what your cholesterol is doing today. What it can do is flag whether you carry an inherited variant that has been statistically associated with higher cholesterol or, separately, with bleeding on certain blood-thinning drugs. Because this is a research-grade marker, the information is best used as one input alongside your actual lipid numbers and clinical picture, not as a stand-alone driver of medical decisions.

What This Gene Actually Does

ABCA6 belongs to a large family of cellular pumps called ATP-binding cassette transporters. These are proteins that use energy to move substances across cell membranes. Within that family, the ABCA subgroup is closely tied to handling fats and cholesterol. ABCA6 sits on chromosome 17 in a cluster with several relatives, including ABCA5, ABCA8, ABCA9, and ABCA10, suggesting they are switched on and off together.

Unlike some of its better-known relatives that sit on the outer surface of cells, ABCA6 appears to work mostly inside the cell, on internal membrane structures such as the Golgi apparatus, where it responds to cholesterol levels. The exact cargo it moves and its full job in the body have not been fully mapped in human research. Even with that uncertainty, the gene has been linked statistically to cholesterol biology, which is why specific variants in it draw attention. This test is a research-grade marker. Standardized clinical cutoffs do not exist, and a single read should not drive medical decisions on its own.

The Cholesterol Connection

The clearest human evidence comes from a large Dutch study that analyzed genetic data from about 35,000 people. It identified a rare protein-changing variant in ABCA6 called rs77542162 (p.Cys1359Arg), present in roughly 3.4% of the population studied. Carriers had measurably higher LDL cholesterol and higher total cholesterol than non-carriers.

The size of that lipid effect was notable. The reported impact on LDL and total cholesterol was similar in magnitude to that of single variants in classic cholesterol genes, including LDLR, which is the gene behind familial hypercholesterolemia. That comparison is about the strength of the statistical association, not a claim that ABCA6 plays an equivalent disease-causing role.

A 2021 follow-up study tested this idea directly in cell culture and in mice and hamsters. While the rs77542162 variant did disrupt ABCA6 protein stability, the researchers found no evidence that ABCA6 actually regulates lipoprotein metabolism in those animal models. In other words, the human statistical signal is real, but the underlying biology has not been confirmed, and the variant may be tagging some other nearby effect rather than acting through ABCA6 itself.

Ancestry matters here. This particular ABCA6 variant was about 3.65 times more common in the Dutch population than in other groups studied. The interpretive value of carrying it therefore depends on background and on what your actual cholesterol numbers look like.

What This Means for Your Heart Risk Picture

If you carry the lipid-associated ABCA6 variant, the practical implication is modest: it may be one part of the explanation for an LDL number that runs higher than your lifestyle would predict. It does not replace measuring LDL, ApoB, or Lp(a), and given the unconfirmed biology, it should not on its own change treatment thresholds. The lipid numbers themselves remain the main signal.

Direct evidence linking ABCA6 variants to heart attacks, strokes, or cardiovascular death has not been demonstrated in the available studies. The lipid statistical signal is real, but the leap from that signal to hard outcomes still rests on the well-established connection between higher LDL and higher cardiovascular risk, not on ABCA6 outcome data.

Bleeding Risk on Rivaroxaban

A separate human study looked at older adults taking the blood thinner rivaroxaban and used whole-exome sequencing to ask why some of them bled while others did not. A different ABCA6 variant, rs7212506, was associated with more bleeding events: people carrying two copies of the variant form (the TT genotype) had about 1.67 times the odds of bleeding. This came from a single small study.

A later, larger study of rivaroxaban-treated patients also examined rs7212506. It saw a weak association with peak anti-Factor Xa drug levels that did not hold up after correcting for multiple statistical tests, and the variant was not identified as a hemorrhage risk factor in that cohort. Two recent systematic reviews of rivaroxaban pharmacogenetics, published in 2024 and 2025, concluded that current data are not sufficient to confirm a relationship between gene variants and rivaroxaban outcomes, and recommended clinical strategies over routine genetic testing.

ABCA6 is not an established drug transporter for rivaroxaban. The main transporters involved in handling this drug are ABCB1 (P-glycoprotein) and ABCG2 (BCRP). Any mechanism by which an ABCA6 variant would influence rivaroxaban handling is speculative at this point. If you are on or considering rivaroxaban, this is not a routine test to order before starting. If you have had unexplained bleeding on the drug, the result may be worth mentioning to your clinician as part of a broader medication safety conversation, but it should not drive decisions on its own.

Reading a Counterintuitive Picture

ABCA6 evidence can feel scattered because it touches different parts of the body through different variants. A variant that has been associated with cholesterol is not the same variant that has been associated with rivaroxaban handling. This is normal for genes that may do more than one thing. Think of ABCA6 less as a single switch and more as a gene with several specific DNA changes that researchers are still trying to understand. The test result tells you which of those specific changes, if any, you carry.

Your One-Time Result

Your ABCA6 genotype is fixed. You were born with it, and the result will be the same if you tested again next year or in thirty years. There is no value in repeating this specific test once you have a confident result from a clinical-grade lab. The value comes from how you use the result over decades.

What does deserve ongoing tracking is the downstream picture your genotype may shape. If you carry the lipid-associated ABCA6 variant, get a baseline lipid panel that includes ApoB and Lp(a), then retest at least annually. If you make lifestyle or medication changes, recheck in 3 to 6 months to see whether they moved your numbers. The ABCA6 read is background context. Your actual lipids are the dashboard.

When Genetic Results Can Be Misleading

Genetic tests come with their own set of caveats that differ from blood biomarker tests.

• Variant panel coverage: this kind of test detects only the specific variants the assay is designed to detect. A result that does not flag a known risk variant does not rule out rare variants in the same gene that were not on the panel.
• Ancestry effects: some ABCA6 variants are much more common in certain populations, such as the lipid-associated variant being roughly 3.65 times more frequent in Dutch individuals. The same result can carry different meaning depending on background.
• Variants of uncertain significance: sequencing may turn up changes in ABCA6 whose meaning is not yet known. These are not actionable on their own and should not be treated as either reassuring or alarming.
• Unconfirmed biology: even for variants with strong human statistical signals, follow-up laboratory work has not confirmed that ABCA6 itself drives the associated effect. Treat results as one input rather than a clear-cut diagnosis.
• Clinical-grade versus direct-to-consumer assays: results from a consumer ancestry-style report can be misread by analysis software and have shown high false-positive rates compared with clinical sequencing. If a consumer test suggests a meaningful ABCA6 variant, confirm it through a clinical lab before acting on it.

What to Do With an Out-of-Pattern Result

If your ABCA6 result flags a cholesterol-associated variant, the workup does not center on the gene itself. It centers on the lipid numbers it may be associated with. The pathway looks like this:

• Confirm and contextualize: if the result came from a consumer test, get a confirmatory clinical-grade test before drawing any conclusions.
• Order a full lipid workup: a basic cholesterol panel is the floor. ApoB gives you a particle count, and Lp(a) covers an inherited risk that a standard panel misses entirely.
• Consider a lipidologist: if your LDL or ApoB is high, a clinician who specializes in inherited lipid disorders can help decide on appropriate thresholds and treatment regardless of the ABCA6 result.
• Family conversations: because the gene is inherited, biological parents, siblings, and children each have a meaningful chance of carrying the same variant. Sharing the result lets them decide whether to test.

If your result flags the rivaroxaban-associated variant, the action is different. Mention it to any clinician considering anticoagulation for you, but recognize that current evidence is preliminary and would not on its own change drug choice.